ReviewToxics2026
Genotoxic, Cytotoxic, and Physiological Effects of Nano- and Microplastics in Invertebrate Model Organisms: Mechanistic Integration, Adverse Outcome Pathways, and Multi-Omics Perspectives.
Review in Toxics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nano- (NPs, <1 µm) and microplastics (MPs, 1 µm-5 mm) are ubiquitous contaminants whose toxicity to invertebrates carries implications at the individual scale and (although not yet quantitatively validated) at the population scale. This semi-systematic narrative review organizes available evidence within an adverse outcome pathway (AOP) framework, linking primary molecular initiating events (MIEs) to adverse outcomes while flagging evidence strength at each step. It involves a structured synthesis that applies selected PRISMA 2020 transparency principles, namely disclosed databases, a priori eligibility criteria, and explicit harvest and de-duplication counts, but does not attempt the exhaustive paired screening, formal risk-of-bias scoring, or quantitative meta-analysis of a full systematic review; this design was chosen because the marked heterogeneity of particle physicochemistry, exposure regimes, and endpoint metrics across the available literature makes pooled statistical synthesis premature. Evidence is appraised across
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.